Confronting COVID-19: Issues in Hemophilia and Congenital Bleeding Disorders

MeSH terms

• Anti-Inflammatory Agents, Non-Steroidal / adverse effects
• Antibodies, Bispecific / therapeutic use
• Antibodies, Monoclonal, Humanized / therapeutic use
• Betacoronavirus*
• COVID-19
• Clinical Trials as Topic
• Comorbidity
• Continuity of Patient Care
• Contraindications, Drug
• Coronavirus Infections / blood
• Coronavirus Infections / complications
• Coronavirus Infections / epidemiology*
• Coronavirus Infections / prevention & control
• Delivery of Health Care
• Disease Management
• Drug Substitution
• Factor IX / supply & distribution
• Factor IX / therapeutic use
• Factor VIII / supply & distribution
• Factor VIII / therapeutic use
• Fibrinolytic Agents / adverse effects
• Fibrinolytic Agents / therapeutic use
• Genetic Therapy
• Health Resources / supply & distribution
• Hemophilia A / complications
• Hemophilia A / epidemiology
• Hemophilia A / therapy*
• Hemophilia B / complications
• Hemophilia B / epidemiology
• Hemophilia B / therapy*
• Hemorrhage / etiology
• Hemorrhage / prevention & control
• Humans
• Pandemics* / prevention & control
• Pneumonia, Viral / blood
• Pneumonia, Viral / complications
• Pneumonia, Viral / epidemiology*
• Pneumonia, Viral / prevention & control
• Professional-Patient Relations
• SARS-CoV-2
• Social Media
• Telemedicine
• Thrombophilia / etiology